Patents by Inventor Tamar H. Michaeli

Tamar H. Michaeli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of identification of inhibitors of PDE1C and methods of treatment of diabetes
    Patent number: 6812239
    Abstract: The present invention provides a method of identifying novel agents that increase glucose dependent insulin secretion in pancreatic islet cells as well as methods of treating diabetes using the agents which have an inhibitory effect on the activity of pancreatic islet cell phosphodiesterases (“PDE”) enzyme, namely PDE1C. The methods described herein are based upon the inventor's surprising discovery that inhibition of PDE1C increases glucose dependent insulin secretion. Specifically, the present invention provides for a method of identifying therapeutic agents that act to increase the release of insulin from pancreatic islet cells. The method of identification provided herein is used to determine the effects of isozyme specific phosphodiesterase inhibitors on insulin secretion from cultured pancreatic &bgr;-cells. Also provided are agents that have an inhibitory effect on the activity of PDE1C in pancreatic cells.
    Type: Grant
    Filed: February 27, 2002
    Date of Patent: November 2, 2004
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventor: Tamar H. Michaeli
  • Method of identification of inhibitors of PDE1C and methods of treatment of diabetes
    Publication number: 20020160939
    Abstract: The present invention provides a method of identifying novel agents that increase glucose dependent insulin secretion in pancreatic islet cells as well as methods of treating diabetes using the agents which have an inhibitory effect on the activity of pancreatic islet cell phosphodiesterases (“PDE”) enzyme, namely PDE1C. The methods described herein are based upon the inventor's surprising discovery that inhibition of PDE1C increases glucose dependent insulin secretion. Specifically, the present invention provides for a method of identifying therapeutic agents that act to increase the release of insulin from pancreatic islet cells. The method of identification provided herein is used to determine the effects of isozyme specific phosphodiesterase inhibitors on insulin secretion from cultured pancreatic &bgr;-cells. Also provided are agents that have an inhibitory effect on the activity of PDE1C in pancreatic cells.
    Type: Application
    Filed: February 27, 2002
    Publication date: October 31, 2002
    Inventor: Tamar H. Michaeli
  • Method of identification of inhibitors of PDE1C
    Patent number: 6417208
    Abstract: The present invention provides a method of identifying novel agents that increase glucose dependent insulin secretion in pancreatic islet cells as well as methods of treating diabetes using the agents which have an inhibitory effect on the activity of pancreatic islet cell phosphodiesterases (“PDE”) enzyme, namely PDE1C. The methods described herein are based upon the inventor's surprising discovery that inhibition of PDE1C increases glucose dependent insulin secretion. Specifically, the present invention provides for a method of identifying therapeutic agents that act to increase the release of insulin from pancreatic islet cells. The method of identification provided herein is used to determine the effects of isozyme specific phosphodiesterase inhibitors on insulin secretion from cultured pancreatic &bgr;-cells. Also provided are agents that have an inhibitory effect on the activity of PDE1C in pancreatic cells.
    Type: Grant
    Filed: February 5, 1999
    Date of Patent: July 9, 2002
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventor: Tamar H. Michaeli